

Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals

Richard DiCicco co-founded Harvest Moon Pharmaceuticals USA, Inc. in 2007 with a proven pipeline of complex generic products developed since 1984. Harvest Moon Pharma develops, manufactures, sells, and/or licenses-out to the trade, worldwide, these complex generic drug products and biosimilars. After seeking scientific advice from the EMA, Harvest Moon Pharma has biosimilars of adalimumab, rituximab and trastuzumab entering phase I clinical trials in Europe. These mAbs were developed in Europe with comparability studies to both the European and USA reference listed biological, are produced in the USA, and comply with the EMA mAb adopted and revised guidelines. These three biosimilars will be filed in Europe and the USA in 2016. Harvest Moon Pharma offers biosimilars of etanercept, infliximab and bevacizumab which will be filed in Europe and the USA in 2017. Mr. DiCicco is a member of the Editorial Board of the Journal of Generic Medicines, a member of the Licensing Executives Society, speaks often and is widely published in generics, biosimilars and the emerging markets of MENA, APAC and BRICKTM.